Type 2 Diabetes and Parkinson's Disease : A Focused Review of Current Concepts
© 2022 International Parkinson and Movement Disorder Society..
Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing of certain antidiabetic medications for the treatment of PD has shown early promise in clinical trials, suggesting that the effects of T2D on PD pathogenesis may be modifiable. The high prevalence of T2D means that a significant proportion of patients with PD may benefit from personalized antidiabetic treatment approaches that also confer neuroprotective benefits. Therefore, there is an immediate need to better understand the mechanistic relation between these conditions and the specific molecular pathways affected by T2D in the brain. Although there is considerable evidence that processes such as insulin signaling, mitochondrial function, autophagy, and inflammation are involved in the pathogenesis of both PD and T2D, the primary aim of this review is to highlight the evidence showing that T2D-associated dysregulation of these pathways occurs not only in the periphery but also in the brain and how this may facilitate neurodegeneration in PD. We also discuss the challenges involved in disentangling the complex relationship between T2D, insulin resistance, and PD, as well as important questions for further research. © 2022 International Parkinson and Movement Disorder Society.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Movement disorders : official journal of the Movement Disorder Society - 38(2023), 2 vom: 03. Feb., Seite 162-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cullinane, Patrick W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hypoglycemic Agents |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 09.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mds.29298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350791643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350791643 | ||
| 003 | DE-627 | ||
| 005 | 20231226045811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mds.29298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350791643 | ||
| 035 | |a (NLM)36567671 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cullinane, Patrick W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type 2 Diabetes and Parkinson's Disease |b A Focused Review of Current Concepts |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 09.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 International Parkinson and Movement Disorder Society. | ||
| 520 | |a Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing of certain antidiabetic medications for the treatment of PD has shown early promise in clinical trials, suggesting that the effects of T2D on PD pathogenesis may be modifiable. The high prevalence of T2D means that a significant proportion of patients with PD may benefit from personalized antidiabetic treatment approaches that also confer neuroprotective benefits. Therefore, there is an immediate need to better understand the mechanistic relation between these conditions and the specific molecular pathways affected by T2D in the brain. Although there is considerable evidence that processes such as insulin signaling, mitochondrial function, autophagy, and inflammation are involved in the pathogenesis of both PD and T2D, the primary aim of this review is to highlight the evidence showing that T2D-associated dysregulation of these pathways occurs not only in the periphery but also in the brain and how this may facilitate neurodegeneration in PD. We also discuss the challenges involved in disentangling the complex relationship between T2D, insulin resistance, and PD, as well as important questions for further research. © 2022 International Parkinson and Movement Disorder Society | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a insulin | |
| 650 | 4 | |a molecular mechanisms | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a de Pablo Fernandez, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a König, Annekatrin |e verfasserin |4 aut | |
| 700 | 1 | |a Outeiro, Tiago Fleming |e verfasserin |4 aut | |
| 700 | 1 | |a Jaunmuktane, Zane |e verfasserin |4 aut | |
| 700 | 1 | |a Warner, Thomas T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Movement disorders : official journal of the Movement Disorder Society |d 1995 |g 38(2023), 2 vom: 03. Feb., Seite 162-177 |w (DE-627)NLM012945846 |x 1531-8257 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:2 |g day:03 |g month:02 |g pages:162-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mds.29298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 2 |b 03 |c 02 |h 162-177 | ||